Much as clinicians will often take a new idea or a newly approved technology and "run with it," devising and testing uses that weren't initially apparent, researchers in eye diseases are expanding the uses and potential of a host of different concepts. Our Annual ARVO Report reflects that approach.


Themes that have been at the forefront for the past few meetings—anti-VEGF in retina, endothelial and lamellar keratoplasty, toric and premium-channel intraocular lenses—continued this year to dominate the attention of vision researchers around the world.

But there are new ideas on the horizon reflected here that may well find their way to a broader audience before long. Radiation treatment for choroidal neovascularization, collagen cross-linking to alleviate keratoconus, and new concepts in dry eye are a few of those.


As every year, we have reviewed thousands of ARVO abstracts in six subspecialty areas shown on the right, and with the invaluable input of our various Section Editors and contributing physicians, we have highlighted those that may have the most clinical applicability, noteworthiness or potential for significant impact on your patients. We've tended to select studies that were not commercially supported, but not exclusively. Many of those that were deemed worth reporting are included, with their declared support indicated. Also, at the end of each abstract's description, you'll see a reference number, which indicates its ARVO program number. The abstracts are edited for space so if you're looking for more information on a specific report, you can find it at arvo.org.